O36.019

Clinical Causes: Mother being Rh-negative (lacking the D antigen on red blood cells). Mother having previous pregnancies or transfusions that exposed her to Rh-positive blood. Development of Anti-D antibodies as an immune response to Rh-positive fetal blood cells crossing into the mother's bloodstream. Absence of preventive measures such as Rh immunoglobulin (RhIg) administration during pregnancy and after potential sensitizing events. Pregnancy in a woman with known Rh incompatibility history.

Key Symptoms: No direct symptoms in the mother from Anti-D antibodies. Potential signs of HDFN in fetus or newborn, such as jaundice, anemia, or swelling. In cases where HDFN develops, the fetus may experience growth restriction or signs of fluid buildup (hydrops fetalis). In newborns, symptoms may include pale skin, lethargy, and a high level of bilirubin resulting in jaundice. Severe cases might lead to complications like heart failure or stillbirth if untreated.

Diagnosis Path: Diagnosis involves blood tests to detect Anti-D [Rh] antibodies in the mother's blood. Blood typing of the mother and fetus, when possible, helps determine Rh compatibility. Ultrasound scans may be used to monitor fetal health, assess for signs of anemia or hydrops fetalis, and overall well-being. In some cases, amniocentesis or fetal blood sampling may be performed to evaluate the severity of fetal anemia and guide management.

Treatment Protocols: Administering Rh immunoglobulin (RhIg) to Rh-negative pregnant women to prevent antibody formation, ideally during pregnancy and within 72 hours after potential sensitizing events. Regular blood tests to monitor antibody levels and assess the risk to the fetus. Ultrasound examinations to evaluate fetal health, including measurements and assessment for signs of anemia. In cases of fetal anemia, intrauterine transfusions may be performed to treat the fetus directly. Planning for delivery based on fetal status; earlier delivery may be considered if fetal health is compromised. Postnatal treatment includes phototherapy for jaundice, blood transfusions for anemia, and close monitoring of the newborn’s condition.